Shares of COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) have earned a consensus recommendation of "Buy" from the six brokerages that are presently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $33.60.
Several research analysts have issued reports on CMPS shares. Maxim Group lowered their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating for the company in a report on Friday, November 1st. HC Wainwright lowered their price target on shares of COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating for the company in a report on Friday, November 1st. Finally, Royal Bank of Canada restated an "outperform" rating and set a $18.00 price target on shares of COMPASS Pathways in a report on Wednesday, January 15th.
Get Our Latest Stock Report on COMPASS Pathways
COMPASS Pathways Price Performance
Shares of CMPS traded down $0.36 during mid-day trading on Friday, reaching $4.11. The company had a trading volume of 958,551 shares, compared to its average volume of 1,339,266. The company's 50 day simple moving average is $4.10 and its 200 day simple moving average is $5.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. COMPASS Pathways has a 1-year low of $3.16 and a 1-year high of $12.75. The company has a market capitalization of $281.21 million, a price-to-earnings ratio of -1.87 and a beta of 2.28.
Institutional Trading of COMPASS Pathways
Several institutional investors have recently made changes to their positions in CMPS. China Universal Asset Management Co. Ltd. bought a new position in COMPASS Pathways during the fourth quarter valued at about $41,000. Wealthfront Advisers LLC bought a new position in COMPASS Pathways during the fourth quarter valued at about $43,000. Flagship Harbor Advisors LLC bought a new position in COMPASS Pathways during the fourth quarter valued at about $43,000. Conservest Capital Advisors Inc. grew its position in COMPASS Pathways by 28.9% during the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock valued at $51,000 after buying an additional 3,000 shares during the period. Finally, Simplify Asset Management Inc. bought a new position in COMPASS Pathways during the fourth quarter valued at about $54,000. Institutional investors own 46.19% of the company's stock.
COMPASS Pathways Company Profile
(
Get Free ReportCOMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Further Reading
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
